NelsonLabs.com is best viewed in Chrome, Firefox, Safari, and Internet Explorer 9 and above.

News Articles

ARTICLE

Posted: June 22, 2017

Marketing Hospital Textiles in the EU Market

By Janelle Bentz, MS
Published: Nonwovens Report International (Issue 4)

Complications after surgical procedures are a major cause of death and disability worldwide. These complications are often caused by bacteria that are typically safe, but they lead to healthcare acquired infections (HAIs) when they breach the sterile field during operation. The sterile field is maintained in the surgical suite by the use of protective barriers, such as surgical drapes, gowns and clean air suits.

→ Read Full Story

ARTICLE

Posted: May 18, 2017

Is Your Biocompatibility Program on the Edge?

By Thor Rollins
Pblished: Medical Products Outsourcing Magazine

Regulatory changes in both Europe and the U.S. have created uncertainty among device makers.

→ Read Full Story

ARTICLE

Posted: April 3, 2017

Extractable/Leachable Chemistry Testing Strategies for Medical Devices

By Matthew R Jorgensen, Ph.D., and Thor Rollins, BS, Nelson Laboratories; Allison Komiyama, Ph.D., RAC, AcKnowledge RS
Published: Medical Device Outsourcing 

It has become more prevalent and acceptable to use the results of chemistry testing to assess the overall biocompatibility of medical devices. For many devices with prolonged or permanent patient contact, chemistry followed by toxicological assessment can provide a cost and time saving alternative to in vivo tests such as chronic, sub-chronic, genetic, and carcinogenicity testing. Manufacturers preparing to submit their device for approval by the U.S. Food and Drug Administration (FDA) rely on ISO 10993 standards and FDA guidance on the application of those standards in the planning of their chemistry testing. When it comes to the details of chemistry testing, however, the ISO standards are often vague. Furthermore, the recommendations regarding the appropriate level of testing rigor can vary within FDA. The following offers a brief overview of the framework provided by ISO 10993 guidance documents for extractable/leachable (E/L) testing, as well as three testing strategies that satisfy both ISO 10993 and FDA requirements.

→ Read Full Story

ARTICLE

Posted: January 17, 2017

A "Particle" of Prevention Is Worth a Pound of Cure: The Significant Benefits of Premarket & Postmarket Particulate Testing of Cardiovascular Devices

The Significant Benefits of Premarket & Postmarket Particulate Testing of Cardiovascular Devices

→ Read Full Story

ARTICLE

Posted: December 21, 2016

How Chemical Characterization Can Supplement and Support Biocompatibility Testing

By Sarah Campbell, PhD; Thor Rollins; Audrey Turley

Using analytical chemistry and data from the compound libraries to assess the finished device can yield more specific data about these extractable compounds than biocompatibility testing. The known properties of the compounds can then be used to create a toxicological risk or safety assessment based on the predicted biological response to the compounds. Download the whitepaper to learn more.

→ Read Full Story

Chat Now